MYC and aneurysmal bone cyst: Nearly 80% of the residues of c-MYC that interacts with USP37 have been found interacting with the designed peptide, suggesting that the peptide is specific to c-MYC-USP37 complex and could be used for targeted therapy against the ABC subtype of DLBCL.